Palbociclib Sandoz Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Palbociclib

Indications/Uses

Patients w/ hormone receptor +ve human epidermal growth factor receptor 2 -ve advanced or metastatic breast cancer in combination w/ aromatase inhibitor as initial endocrine-based therapy or fulvestrant in patients w/ disease progression following endocrine therapy.

Dosage/Direction for Use

125 mg once daily for 21 consecutive days followed by 7 days off treatment (schedule 3/1) to complete 28 days cycle. Severe hepatic impairment 75 mg once daily on schedule 3/1.

Administration

Should be taken with food: Swallow whole, do not chew/crush/open.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EF01 - palbociclib ; Belongs to the class of cyclin-dependent kinase (CDK) inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Palbociclib Sandoz hard cap 100 mg

Packing/Price

1's

Form

Palbociclib Sandoz hard cap 125 mg

Packing/Price

1's

Form

Palbociclib Sandoz hard cap 75mg

Packing/Price

1's

Palbociclib Sandoz

palbociclib

Manufacturer:

Aizant Drug Research Solutions